相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Barnaby Edward Young et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
Dawei Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak
A. Wilder-Smith et al.
JOURNAL OF TRAVEL MEDICINE (2020)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Guangdi Li et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The COVID-19 epidemic
Thirumalaisamy P. Velavan et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2020)
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Canrong Wu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Markus Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients
Jing Yuan et al.
INFLAMMATION RESEARCH (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds
Andre Fischer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Eli S. Rosenberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
Safiya Richardson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
Giacomo Grasselli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
Sara Baldelli et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine
Paul Elias Alexander et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Lisi Deng et al.
JOURNAL OF INFECTION (2020)
Against pandemic research exceptionalism
Alex John London et al.
SCIENCE (2020)
The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections
Farhana Musarrat et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China
Qiang Ding et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao et al.
BIOSCIENCE TRENDS (2020)
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
Zhenwei Wang et al.
BIOSCIENCE TRENDS (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu et al.
JAMA INTERNAL MEDICINE (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
Arbidol/IFN-a2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study
Ping Xu et al.
MICROBES AND INFECTION (2020)
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
Mingxing Huang et al.
NATIONAL SCIENCE REVIEW (2020)
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
Nicholas J. Mercuro et al.
JAMA CARDIOLOGY (2020)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Joshua Geleris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
Markus Hoffmann et al.
NATURE (2020)
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Brandi N. Williamson et al.
NATURE (2020)
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse et al.
NATURE (2020)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
David R. Boulware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management
Mina T. Kelleni
PHARMACOLOGICAL RESEARCH (2020)
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
Andrea J. Pruijssers et al.
CELL REPORTS (2020)
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Christoph D. Spinner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Family cluster of three recovered cases of pneumonia due to severe acute respiratory syndrome coronavirus 2 infection
Yong Xiong et al.
BMJ CASE REPORTS (2020)
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Egor P. Tchesnokov et al.
VIRUSES-BASEL (2019)
Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
Francois Ferron et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
Rameshwar U. Kadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
Mizuki Yamamoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Computational methods in drug discovery
Sumudu P. Leelananda et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2016)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
Coronaviruses - drug discovery and therapeutic options
Alimuddin Zumla et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Protease inhibitors targeting coronavirus and filovirus entry
Yanchen Zhou et al.
ANTIVIRAL RESEARCH (2015)
Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
Julie Dyall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Jean-Francois Rossignol
ANTIVIRAL RESEARCH (2014)
Arbidol as a broad-spectrum antiviral: An update
Julie Blaising et al.
ANTIVIRAL RESEARCH (2014)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2013)
Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model
Yiwu Yan et al.
CELL RESEARCH (2013)
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Jasper F. W. Chan et al.
JOURNAL OF INFECTION (2013)
Hydroxychloroquine: From Malaria to Autoimmunity
Ilan Ben-Zvi et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2012)
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
Mark S. Sulkowski et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials
Andrew Hill et al.
AIDS (2009)
Survival after massive hydroxychloroquine overdose
N. Gunja et al.
ANAESTHESIA AND INTENSIVE CARE (2009)
Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel
Scott M. Hammer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
Jean-Marc Rolain et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
New insights into the antiviral effects of chloroquine
A Savarino et al.
LANCET INFECTIOUS DISEASES (2006)
SARS: Systematic review of treatment effects
Lauren J. Stockman et al.
PLOS MEDICINE (2006)
Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity
F Romanelli et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
N Yamamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
I Hamming et al.
JOURNAL OF PATHOLOGY (2004)
Practical guidelines to interpret plasma concentrations of antiretroviral drugs
BS Kappelhoff et al.
CLINICAL PHARMACOKINETICS (2004)
Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada
SR Knowles et al.
CLINICAL INFECTIOUS DISEASES (2003)
Ribavirin's antiviral mechanism of action: lethal mutagenesis?
S Crotty et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
Fatal toxic epidermal necrolysis associated with hydroxychloroquine
M Murphy et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2001)
分享论文
